Aptamer Group - About the company
Aptamer Group is a public company based in York (United Kingdom), founded in 2008. It operates as a Manufacturer of DNA and RNA nucleic acid aptamers for use in research & development. Aptamer Group has raised $2.2M in funding from Meneldor. The company has 26 active competitors, including 4 funded and 6 that have exited. Its top competitors include companies like Aptamer Sciences, Base Pair Biotechnologies and Apta Biotech.
Company Details
Manufacturer of DNA and RNA nucleic acid aptamers for use in research & development. The company develops aptamer molecules derived from nucleic acids by using Optimer technology that functions as an antibody alternative. The Optimer binders are used for research and tool reagents, biomarker discovery and diagnostic development, and as therapeutic lead compounds.
- Website
- aptamergroup.com
- Email ID
- *****@aptamergroup.com
- Phone Number
- +44 **********
Key Metrics
Founded Year
2008
Location
York, United Kingdom
Stage
Public
Total Funding
$2.2M in 5 rounds
Latest Funding Round
Ranked
1st among 26 active competitors
Annual Revenue
£1M - £10M as on Jun 30, 2025
Employee Count
46 as on Oct 31, 2026
Similar Companies
Exit Details
Public
Legal entities associated with Aptamer Group
Aptamer Group is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
APTAMER GROUP PLC CIN: 9061413 , United Kingdom, Active | May 28, 2014 | £1M - £10M (As on Jun 30, 2025) | 19 (As on Mar 31, 2020) |
Aptamer Group's IPO details
Aptamer Group got listed on Dec 22, 2021.
Click here to take a look at Aptamer Group's IPO in detail
Sign up to download Aptamer Group's company profile
Aptamer Group's funding and investors
Aptamer Group has raised a total funding of $2.2M over 5 rounds. Its first funding round was on Jun 26, 2018. Aptamer Group has 5 institutional investors.
Here is the list of recent funding rounds of Aptamer Group:
Filter this list
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jul 04, 2025 | 7794156 | Post IPO | 9683981 | 4050134 | 1937334 | 2975349 |
Jul 24, 2024 | 4808607 | Post IPO | 5196165 | 5337446 | 2048820 | |
Sep 19, 2023 | 5084010 | Post IPO | 7766808 | 7027478 | 3305564 | 3573385 |
View details of Aptamer Group's funding rounds and investors
Aptamer Group's founders and board of directors
Founder? Claim ProfileAptamer Group's employee count trend
Aptamer Group has 46 employees as of Oct 26. Here is Aptamer Group's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Aptamer Group's Competitors and alternates
Top competitors of Aptamer Group include Aptamer Sciences, Base Pair Biotechnologies and Apta Biotech. Here is the list of Top 10 competitors of Aptamer Group, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Aptamer Group 2008, York (United Kingdom), Public | Manufacturer of DNA and RNA nucleic acid aptamers for use in research & development | $2.2M | 59/100 | |
2nd | Aptamer Sciences 2011, Pohang si (South Korea), Public | Aptamer technology platform for protein analysis | - | 49/100 | |
3rd | Base Pair Biotechnologies 2011, Pearland (United States), Public | Aptamer discovery and development services for diagnostics, therapeutics, and research | $5.06M | 42/100 | |
4th | Apta Biotech 2009, Yongin si (South Korea), Public | Provider and developer of aptamers based on platform technology | - | 36/100 | |
5th | Femtogenix 2015, London (United Kingdom), Series B | Provider of DNA-interactive payload molecules for use in ADCs | $40.2M | 35/100 | |
6th | Apta Biosciences 2013, London (United Kingdom), Deadpooled | Developer of a synthetic biology technology platform for diagnostics and therapeutics | $4.51M | 34/100 | |
7th | Aptus Biotech 2010, Madrid (Spain), Seed | Developer of biotechnological applications based on aptamers | - | 33/100 | |
8th | Provider of a platform for discovery and development of XenoAptamers for life sciences applications and research | - | - | 32/100 | |
9th | Archemix 2000, San Francisco (United States), Deadpooled | Aptamer therapeutics for rare hematological diseases | $102M | 31/100 | |
10th | Aptabodies.com 2008, York (United States), Unfunded | Develops and manufactures aptamers | - | - | 30/100 |
Looking for more details on Aptamer Group's competitors? Click here to see the top ones
Aptamer Group's Investments and acquisitions
Aptamer Group has made no investments or acquisitions yet.
Reports related to Aptamer Group
Here is the latest report on Aptamer Group's sector:
News related to Aptamer Group
Media has covered Aptamer Group for a total of 14 events in the last 1 year, 9 of them have been about company updates and 1 about people movement.
•
Aptamer Group Appoints Dr. James McNamara as Head of Oligonucleotide Therapeutic DevelopmentContract Pharma•Nov 16, 2026•Aptamer Group
•
Aptamer Group grows sales pipeline to £7m as it targets break-evenTheBusinessDesk.com•Oct 13, 2026•Aptamer Group
•
Aptamer Group set to report strong growth - reflects “continuedInsider Media•Jul 14, 2026•Aptamer Group
•
Aptamer revenues climb as York biotech delivers first licensing incomeTheBusinessDesk.com•Jul 13, 2026•Aptamer Group
•
Aptamer Group Begins Development of Rapid Test for Bundibugyo EbolaContract Pharma•Jul 08, 2026•Aptamer Group
•
TRADING UPDATES: Caspian reports progress; Arkle nears Erongo drillingShareprices•Jun 25, 2026•Aptamer Group, Arkle Resources, CRISM Therapeutics, Caspian Sunrise
•
Aptamer Announces First-Half Progress and Plans to Raise FundsShareprices•Mar 25, 2026•Aptamer Group
•
Aptamer Group Introduces Targeted Radiopharmaceutical ProgramContract Pharma•Mar 18, 2026•Aptamer Group
•
Aptamer lifts revenues as licensing strategy gains momentumTheBusinessDesk.com•Jan 07, 2026•Aptamer Group
•
Aptamer signs Optimer contract with US biotech AlphazymeShareprices•Dec 23, 2025•Aptamer Group, Alphazyme
Are you a Founder ?
FAQs about Aptamer Group
Explore our recently published companies
- Ottoventi - Italy based, Unfunded company
- Jennifer Rempel Art - United States based, 1986 founded, Unfunded company
- Naples Ambulance - United States based, Funding Raised company
- Summit Woodwork - San Clemente based, Unfunded company
- Iuventa Finance - Berlin based, 1999 founded, Unfunded company
- Hartog lucerne - Medemblik based, 1952 founded, Acquired company